תאוריית התגובה ההפוכה לצורך בדיקת דירוג חד-צדדי במטריצות תגובה של תרופות נגד סרטן

תקציר מקורי באנגליתarXiv:2610.00002v1 Announce Type: new Abstract: We introduce reverse Item Response Theory (IRT) to pharmacogenomic drug-response analysis by treating cancer types as latent "subjects" with resistance ability and drugs as "items" with evasion difficulty. Applied to 242,036 drug sensitivity measurements from the Genomics of Drug Sensitivity in Cancer (GDSC2) database, the model estimates cancer-type-level in-vitro resistance and drug-level broad activity on a shared latent scale. Validation across four missingness regimes demonstrates that reverse IRT better recovers the full-data latent ranking than simple averaging, with advantages of Delta-rho = +0.089 to +0.095 at 60% missingness under MCAR, cancer-biased, and drug-biased sparsity. Held-out prediction confirms IRT achieves the best Brier